Gelonghui September 24th | Gan & Lee Pharmaceuticals (603087.SH) stated on the investor interaction platform that the company's three insulin products have officially been accepted by the FDA/EMA for substantive review. In May 2024, the company has passed the pre-approval GMP inspection of the EU EMA.
甘李药业(603087.SH)：公司三款胰岛素产品已获得FDA/EMA正式受理进入实质审查阶段
Gan & Lee Pharmaceuticals (603087.SH): The company's three insulin products have officially been accepted by the FDA/EMA for substantive review.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated